Clinical Study
Association of One-Step Nucleic Acid Amplification Detected Micrometastases with Tumour Biology and Adjuvant Chemotherapy
Table 2
Tumour characteristics of patients who underwent adjuvant chemotherapy.
| | | Pre-OSNA | Post-OSNA | | | (2009–2012) | (2013) |
| | Number of patients (n/%) | 21 | 23 | | Age (range) | 54 (39–69) | 53 (32–74) | | Screen detected | 6 (28.5%) | 6 (26%) | | Tumour size (mm) | 26.5 | 21.8 | | Tumour grade (n/%) | | | | Grade 1 | 1 (5%) | 0 (0%) | | Grade 2 | 12 (57%) | 7 (30%) | | Grade 3 | 8 (38%) | 16 (70%) | | ER receptor (n/%) | | | | Positive | 17 (80.9%) | 14 (60.8%) | | Negative | 4 (19.1%) | 8 (38%) | | Borderline | 0 | 1 (1.2%) | | HER-2 receptor (n/%) | | | | Positive | 2 (9.5%) | 6 (25.1%) | | Negative | 19 (90.5%) | 17 (73.9%) | | Triple negative (n/%) | 4 (19%) | 6 (26%) | | Predicted 10-year survival benefit with chemotherapy >3% | 11 (52%) | 16 (70%) |
|
|
